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Protein kinase C (PKC) isozymes exhibit important
differences in terms of their regulation and biological
functions. Not only may some PKC isoforms be active
and others not for a given response, but the actions of
different isoforms may even be antagonistic. In NIH 3T3
cells, for example, PKCd arrests cell growth whereas
PKCe stimulates it. To probe the contribution of the
regulatory and the catalytic domains of PKC isozymes to
isozyme-specific responses, we prepared chimeras be-
tween the regulatory and the catalytic domains of
PKCa, -d, and -e. These chimeras, which preserve the
overall structure of the native PKC enzymes, were sta-
bly expressed in mouse fibroblasts. A major objective
was to characterize the growth properties of the cells
that overexpress the various PKC constructs. Our data
demonstrate that both the regulatory and the catalytic
domains play roles in cell proliferation. The regulatory
domain of PKCe enhanced cell growth in the absence or
presence of phorbol 12-myristate 13-acetate (PMA), and,
in the presence of PMA, all chimeras with the PKCe
regulatory domain also gave rise to colonies in soft agar;
the role of the catalytic domain of PKCe was evident in
the PMA-treated cells that overexpressed the PKC chi-
mera containing the d regulatory and the e catalytic
domains (PKCd/e). The important contribution of the
PKCe catalytic domain to the growth of PKCd/e-express-
ing cells was also evident in terms of a significantly
increased saturation density in the presence of PMA,
their formation of foci upon PMA treatment, and the
induction of anchorage-independent growth. Aside from
the growth-promoting effect of PKCe, we have shown
that most chimeras with PKCa and -d regulatory do-
mains inhibit cell growth. These results underscore the
complex contributions of the regulatory and catalytic
domains to the overall behavior of PKC.
Protein kinase C (PKC)1 comprises a family of serine/threo-
nine kinases that play crucial roles in signal transduction and
in the regulation of cell growth and differentiation (1, 2). The
complexity of the PKC pathway is clearly shown by the fact
that PKC represents at least 11 isozymes with different pat-
terns of tissue expression, subcellular localization and cofactor
requirements as well as functional diversity (3, 4).
In all cases, the PKC isozymes consist of an N-terminal
regulatory domain and a C-terminal catalytic domain. The
catalytic domain has serine/threonine-specific protein kinase
activity. In the “classical” (a, bI, bII, g) and “novel” (d, e, h, u)
PKC isozymes, the regulatory domain is thought to inhibit this
catalytic activity through a so-called pseudosubstrate region
near its N terminus. Adjacent to this pseudosubstrate region is
a pair of highly conserved zinc finger structures, which repre-
sent the phorbol ester binding domain and which contribute to
the interaction with an essential cofactor, anionic phospholipid
(5). Diacylglycerol, the endogenous activator, and its ultrapo-
tent analogs, the phorbol esters, act as hydrophobic switches
upon binding (6), helping to recruit protein kinase C to the
membrane (7), a process referred to as translocation.
Not only do the various isozymes show considerable diversity
in their structures and regulatory properties, but they have
been shown to exhibit different biological effects (1, 8). PKCa
and -e were shown to inhibit phospholipase C activity (9), and
PKCb and -e were proven to link the mast cell high affinity
receptor for IgE to the expression of c-fos and c-jun (10). PKCd
and -a participate in phorbol 12-myristate 13-acetate (PMA)-
induced myeloid differentiation in 32D cells (11). Of particular
relevance to the current study, PKCd and -e have been shown
by several groups to be involved in arresting or stimulating cell
growth, respectively. PKCd was shown to decrease cell growth,
reduce cell density at confluence and not to permit anchorage-
independent growth in NIH 3T3 fibroblasts (12), and to cause
growth arrest in G2/M phase of the cell cycle in Chinese ham-
ster ovary cells (13). A recent study showed that, in rat fibro-
blasts that overexpress the c-src proto-oncogene, the tumor-
promoting effect of phorbol esters is due to depletion of PKCd,
further supporting its tumor suppressor function (14). In con-
trast, overexpression of PKCe leads to increased cell growth,
increased cell density at confluence, and induction of anchor-
age-independent growth in NIH 3T3 and rat fibroblasts (12,
15). Overexpression of PKCe in these cells also renders them
tumorigenic in nude mice (12, 15). Against this background, it
is crucial to emphasize that the effect of PKC isozymes is
greatly influenced by the host cell; PKCd enhances tumorige-
nicity of breast cancer cells and may thus promote tumor pro-
gression in that system (16). This cell type-specific function
also holds for the PKCa and -bII isotypes, which play distinct
roles in the transduction of proliferative and differentiating
signals in K-562 erythroleukemia cells; PKCa inhibits whereas
PKCbII promotes cell growth (17). Similar results were ob-
tained using the R6 rat embryo fibroblast cell line (18). On the
other hand, PKCa, like PKCd, enhances the growth rate of
breast cancer cells making them display a more aggressive
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neoplastic phenotype (19).
The fact that PKCa, PKCd, and PKCe cause opposite effects
in stimulating and inhibiting cell growth makes them attrac-
tive targets for antitumor drug development. To probe the
contribution of the regulatory and the catalytic domains of PKC
isozymes to isozyme-specific responses, we prepared reciprocal
chimeras between the regulatory and the catalytic domains of
PKCa, -d, and -e, combined at the highly conserved hinge
region. We describe here the effects caused by overexpression of
these chimeric enzymes on cell growth of NIH 3T3 fibroblasts.
We found that both the regulatory and the catalytic domains of
PKC contributed to the isotype-specific effects on cell growth.
EXPERIMENTAL PROCEDURES
Construction of PKC Chimeras—Protein kinase C chimeras were
generated by swapping the regulatory and the catalytic domains of
PKCa, PKCd, and PKCe. The construction of the chimeric proteins is
detailed elsewhere (20). Briefly, the regulatory and the catalytic do-
mains of PKCa, -d, and -e were amplified separately by polymerase
chain reaction employing high fidelity thermostable Vent™ DNA po-
lymerase (New England Biolabs Inc., Beverly, MA). To avoid mutations,
in addition to using high fidelity enzymes, we kept the number of
polymerase chain reaction cycles low (eight cycles). Into the inner
primers we introduced a unique restriction site (SpeI) for subsequent
cloning steps. Using the pGEM-T vector as a shuttle vector, we ampli-
fied the different PKC domains separately by transforming them into
bacteria, then subcloning the regulatory domains into the vectors that
contained the catalytic domains using SpeI and MluI restriction en-
zymes. An important advantage of this approach is that we could
reconstruct the wild type PKCa, -d, and -e using the same inserts as for
the chimeras providing us with wild type controls constructed the same
way as the chimeras. The chimeras along with the wild type PKC
isozymes were subcloned into an epitope tagging mammalian expres-
sion vector described in detail by Olah et al. (21). The XhoI and MluI
sites ensure unidirectionality, and the vector attaches to the end of the
proteins a C-terminal 12-amino acid tag, originally derived from the
C-terminal sequence of PKCe. Our constructs were sequenced by Par-
agon Biotech Inc. (Baltimore, MD) to verify that no mutations had been
introduced. The chimeras were designated as PKCx/y, where x and y
refer to the regulatory and the catalytic domains, respectively. Thus,
PKCa/d, for example, refers to the chimera between the a regulatory
domain and the d catalytic domain.
Cell Culture and Transfection of Cells—NIH 3T3 cells were grown in
Dulbecco’s modified Eagle’s medium supplemented with 4500 mg/liter
glucose, 4 mM L-glutamine, 50 units/ml penicillin, 50 mg/ml streptomy-
cin (Advanced Biotechnologies Inc., Columbia, MD), and 10% fetal calf
serum (Life Technologies, Inc.) (complete DMEM). The cells were trans-
fected with either the empty vector or the different PKC expression
vectors using LipofectAMINE (Life Technologies, Inc.) following the
procedure recommended by the manufacturer. The transfected cells
were subsequently grown in selection medium containing 750 mg/ml
G418 (Life Technologies, Inc.). After 12–18 days in selection medium,
single colonies were picked, expanded, and screened for the presence of
different PKC chimeras by Western blot analysis. Where indicated,
cells were treated with 30 nM PMA (LC Laboratories, Woburn, MA)
every other day for the duration of the experiment; likewise, where
indicated, PDGF (Upstate Biotechnology Inc., Lake Placid, NY) was
added to a 100 ng/ml final concentration after overnight serum
starvation.
Cell Lysis and Western Blot Analysis—The cells were harvested into
20 mM Tris-Cl (pH 7.4) containing 5 mM EGTA, 1 mM 4-(2-aminoethyl-
)benzenesulfonyl fluoride, and 20 mM leupeptin and lysed by sonication.
The samples were subjected to SDS-PAGE according to Laemmli (22)
and transferred to nitrocellulose membranes. Western blots were
stained with 0.1% Ponceau S solution in 5% acetic acid (Sigma) for
determining the protein content of individual lanes. The protein stain-
ing was found to be linear up to 30 mg of protein/lane. The Ponceau S
staining was removed by several washes of phosphate-buffered saline
(pH 7.4); the membranes were blocked with 5% dry milk in phosphate-
buffered saline and subsequently immunostained with antibodies gen-
erated against the C terminus (PKCd amino acids 662–673) of PKCd
(Research & Diagnostics Antibodies, Berkeley, CA), the C terminus of
PKCa (Upstate Biotechnology Inc.) or an affinity-purified polyclonal
antibody against a polypeptide corresponding to amino acids 726–737
of PKCe (Life Technologies, Inc.). Secondary antibodies were goat anti-
rabbit or goat anti-mouse IgG coupled to horseradish peroxidase (Bio-
Rad), and the immunoreactive bands were visualized by the ECL West-
ern blotting detection kit (Amersham).
Growth Curves, Determination of Doubling Times, and Maximal Cell
Numbers—104 cells/well were plated in 12-well plates in triplicate in
complete DMEM in the presence or absence of 30 nM PMA (LC Labo-
ratories, Woburn, MA) and increasing concentrations (0.1 nM-1000 nM)
of the catalytic site-directed PKC inhibitor GF 109203X (bisindolylma-
leimide I) (LC Laboratories). Fresh medium was added every other day,
and cells in triplicate wells were harvested every second day by
trypsinization and counted in a Coulter counter. To determine the
average doubling time, cells were plated the same way, but cells were
trypsinized and counted every 24 h for 7 consecutive days. The average
doubling time was calculated by using the 24-h time point as the
starting point to avoid artifacts due to the initial lag period after plating
(12). To determine the maximal cell density, cells were grown in 12-well
plates to confluence and kept postconfluent for 3 additional days with
daily medium changes. Cells were counted as described above.
Soft Agar Assays—105 cells were resuspended in complete DMEM
containing 0.4% Noble agar (Sigma) in the presence or absence of 30 nM
PMA and were overlaid above a layer of 0.6% Noble agar in complete
DMEM. The cells were fed every fifth day by overlaying the agar with
2 ml of complete medium containing the appropriate amount of PMA.
The presence or absence of colonies was scored after 14 days.
Immunoprecipitation—NIH 3T3 fibroblasts that overexpressed the
PKC chimeras were washed three times with ice-cold phosphate-buff-
ered saline. The cells were scraped from a 60-mm dish into 1 ml of lysis
buffer containing 50 mM HEPES, pH 7.5, 150 mM NaCl, 10% glycerol,
1% Triton X-100, 1.5 mM MgCl2, 10 mg/ml aprotinin, 10 mg/ml leupeptin,
1 mM 4-(2-aminoethyl)benzenesulfonyl fluoride, and 1 mM EGTA. After
mixing, the samples were incubated on ice for 30 min and then centri-
fuged in a microcentrifuge at 4 °C for 5 min. The supernatant was
removed and preabsorbed with 25 ml of Protein A/G-Sepharose (50%)
(Santa Cruz Biotechnology Inc., Santa Cruz, CA) for 10 min; the sam-
ples were then spun at 4 °C for 3 min at 15,000 3 g, and the superna-
tants were taken for immunoprecipitation. Immunoprecipitation was
performed by rotating the samples overnight with 30 ml of Protein
A/G-Sepharose (50%) and 4 mg/ml anti-PKCe antibody (Life Technolo-
gies, Inc.) at 4 °C. The samples were spun at 15,000 3 g at 4 °C for 3 min
and washed three times with radioimmune precipitation buffer contain-
ing 50 mM Tris, pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1%
sodium deoxycholate. The pellets were resuspended in 25 ml of SDS
sample buffer and boiled for 5 min. Before SDS-PAGE, samples were
centrifuged again as described above and the entire supernatants were
subjected to Western blotting and probed with anti-phosphotyrosine
(monoclonal IgG2bk) (Upstate Biotechnology Inc.) and anti-PKCe anti-
bodies (Life Technologies, Inc.).
RESULTS
We constructed reciprocal chimeras from N-terminal and
C-terminal halves of PKCa, PKCd, and PKCe to study the
relative contributions of the regulatory and catalytic subunits
of these isozymes. We chose the first part of the highly con-
served C3 region for the exchange, since the function of this
region is well known and the sequence is identical in all the
different isozymes (23, 24). We engineered the constructs in a
way that allowed us to make wild type PKC isozymes the same
way as the chimeric constructs, thus providing us with proper
positive controls. Having the PKCe tag on our chimeras allowed
better detection in Western blotting and a good epitope for
immunoprecipitation.
First, we determined whether our isozymes can be stably
expressed in NIH 3T3 fibroblasts. For this purpose, cells were
stably transfected with “wild type” PKCa/a, -d/d, -e/e and the
chimeras PKCa/d, -a/e, -d/a, -d/e, -e/a, and -e/d (Fig. 1). To assess
the level of protein production, total cellular protein was col-
lected from five individual antibiotic resistant clones of cells
that overexpressed each isozyme and also from five vector-only
control cell lines, and they were examined by Western blot
analysis using monoclonal anti-PKCa antibodies or polyclonal
anti-PKCd or anti-PKCe antibodies. The antibodies recognized
the two previously described PKCe-specific bands at 90 and 93
kDa (15) of the overexpressed PKCe. As we have described (20),
PKCa/e and PKCd/e chimeras also showed double bands on
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Western blots, suggesting that the PKCe catalytic domain un-
derwent posttranslational phosphorylation similar to the wild
type. At the same time, PKCe/d and -e/a chimeras showed a
single band on Western blots, suggesting that this posttrans-
lational modification of PKCe occurs only on the catalytic do-
main. These data are consistent with the PKC chimeras being
expressed and processed in a fashion similar to the parental
PKC isoforms.
To establish that the overexpressed PKC chimeras were
functionally intact, i.e. display kinase activity and bind phorbol
ester, we assayed in vitro kinase activity and phorbol 12,13-
dibutyrate binding on partially purified cell lysates. All over-
expresser cells exhibited increased phorbol 12,13-dibutyrate
binding and kinase activity as compared with the control cells
transfected with the empty vector, as reported elsewhere (20).
The localization and translocation patterns of the various
chimeras are reported separately (20). All the chimeras are
found predominantly in the soluble fraction, and they all trans-
locate upon PMA treatment. PMA-induced translocation and
targeting of the enzymes are influenced by the catalytic domain
as well as by the regulatory domain (20).
A major objective was to characterize the growth properties
of the cells that overexpressed the various PKC constructs.
Consistent with previous reports (12, 15, 17), our cells that
overexpressed PKCa/a and PKCd/d proliferated significantly
more slowly than the control cells, whereas cells that overex-
pressed PKCe/e had a significantly higher rate of growth. Table
I shows the values for the doubling time both in the presence
and absence of PMA (n 5 3 experiments). In the absence of
PMA chimeras containing the regulatory domain of PKCa grew
significantly more slowly than the control cells (cells trans-
fected with the empty vector), whereas those that contained the
regulatory domain of PKCe had a higher growth rate. It is
important to note, however, that the catalytic domain also
influenced the growth behavior of the chimeras. Thus, cells
that expressed PKCa/e grew fastest of those that expressed
PKCa/y chimeras and, reciprocally, cells that expressed
PKCe/a grew most slowly of the PKCe/y chimeras. Treatment
with 30 nM PMA enhanced the difference between cells express-
ing the different isozymes. This is evident both upon micro-
scopic examination (Fig. 2) and from growth curves (Fig. 3).
This concentration of PMA activates PKC but does not cause
FIG. 1. The expression of PKC chimeras in NIH 3T3 cells. NIH
3T3 fibroblasts that had been stably transfected with overexpressing
vectors were harvested and subjected to SDS-PAGE and Western im-
munoblotting as described under “Experimental Procedures.” The fig-
ure illustrates one representative experiment of five similar experi-
ments. The membrane was probed with anti-PKCe antibody that also
stains the endogenous PKCe. Due to the level of overexpression of the
PKCe/e chimera, the higher and lower mobility bands of PKCe/e men-
tioned in the text do not separate in this figure, but the two bands in the
case of the PKCa/e and PKCd/e chimeras can be easily observed.
FIG. 2. Cultures of NIH 3T3 cells that overexpress the PKC
chimeras, after 7 days of PMA treatment. Overexpressers were
seeded in 12-well plates at 104 cells/well. Cells were treated with 30 nM
PMA as described under “Experimental Procedures.” The figure shows
representative areas of the cell cultures after 7 days of treatment.
TABLE I
Proliferation characteristics of NIH 3T3 cells that overexpress PKC constructs
Control (only bearing the empty vector) NIH 3T3 cells and overexpressers were treated with 30 nM PMA, and the doubling time and the maximal
cell number at saturation were calculated as described under “Experimental Procedures.” Values represent the mean 6 S.E. of three independent
experiments with six determinations of the values in each experiment. Growth in soft agar was determined in the presence and absence of 30 nM
PMA as described under “Experimental Procedures.” *, p , 0.05; **, p , 0.01.
Doubling time Saturation density Growth in soft agar
2PMA 1PMA 2PMA 1PMA 2PMA 1PMA
h 3 105 ;colonies
Control 19.8 6 1.2 25.4 6 0.8 12.4 6 0.4 11.2 6 0.8 0 0
PKCa/a 26.2 6 2.0* 42.7 6 2.8** 10.1 6 1.2 4.1 6 0.6** 0 0
PKCa/d 28.5 6 1.6* 40.8 6 5.2* 11.3 6 0.7 4.3 6 0.8** 0 0
PKCa/e 25.5 6 3.2 34.9 6 4.7 12.2 6 1.2 7.3 6 1.2* 0 0
PKCd/a 26.4 6 2.3* 37.6 6 3.1* 11.8 6 0.6 7.4 6 0.5* 0 0
PKCd/d 25.4 6 1.8 39.4 6 2.8** 12.2 6 0.4 7.0 6 0.6** 0 0
PKCd/e 21.3 6 2.3 23.6 6 1.4 12.8 6 1.3 14.7 6 1.4 0 250
PKCe/a 18.1 6 1.4 22.2 6 1.8 12.6 6 0.6 10.3 6 1.8 0 210
PKCe/d 16.8 6 1.1 21.8 6 0.9* 12.4 6 0.8 12.9 6 1.1 0 300
PKCe/e 14.6 6 1.0* 18.1 6 1.4** 12.8 6 0.6 20.1 6 1.4** 0 520
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down-regulation of the enzyme, as revealed by Western blot-
ting (data not shown). The doubling times of the cells that
overexpressed chimeras containing the regulatory domain of
PKCe were shorter than that of the control cells (demonstrated
in Fig. 3A). We obtained similar data by measuring [3H]thymi-
dine incorporation into these cells with and without PMA treat-
ment (data not shown). The effects of the chimeras on cell
density at confluence were most evident in the presence of PMA
(Table I). Cells expressing PKCe/e and -d/e chimeras grew to the
highest cell density, with the former achieving nearly twice
the saturation density of the control. At the same time cells
expressing PKCe/a and -e/d chimeras saturated at levels
closer to the control cells (demonstrated in Fig. 3B). Overex-
pression of all three chimeras that contained the PKCe reg-
ulatory domain as well as the PKCd/e chimera enabled the
cells to grow and form colonies in soft agar. We observed this
anchorage-independent growth only in the presence of 30 nM
PMA (Table I).
To confirm that the growth alterations observed in these
cells were due to the presence of overexpressed PKC isozymes,
we examined the effect of an inhibitor of PKC catalytic activity,
GF 109203X. Administering increasing concentrations of GF
109203X, we could reverse the effect of the overexpressed pro-
teins in the presence of PMA, consistent with the central role of
PKC in these processes (Fig. 4). Furthermore, cells that over-
expressed PKCe/e and the PKCd/e chimera formed dense foci
and were not contact inhibited. This effect was also blocked by
GF 109203X (data not shown).
PKCd has been reported to be tyrosine-phosphorylated upon
stimulation with PDGF (25). To determine which domain is
involved in this process, we starved the PKC-overexpressing
cells overnight and then treated them with 100 ng/ml PDGF.
After immunoprecipitation and Western blotting we probed the
membranes with anti-phosphotyrosine antibody. PKCd/d,
PKCd/a, and PKCd/e were tyrosine-phosphorylated (Fig. 5),
whereas PKCa/a, -e/e, -e/d, and -a/d were not (data not shown).
This suggests that tyrosine phosphorylation of PKCd upon
PDGF treatment occurred exclusively when the PKCd regula-
tory domain is present, and it is independent of the catalytic
domain.
FIG. 3. Growth curves of NIH 3T3
cells overexpressing PKC chimeras
in the presence of phorbol ester.
Overexpressers were seeded in 12-well
plates at 104 cells/well. Cells were chron-
ically treated with 30 nM PMA as de-
scribed under “Experimental Proce-
dures,” and the cell number was counted
every other day. A shows the cell numbers
during the first 8 days, and B shows the
period between the 8th and 16th days of
the experiment. Values represent the
mean of three independent experiments.
(Error bars were omitted for clarity; the
S.E. was less than 10%.)
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DISCUSSION
The protein kinase C molecule consists of two functional
domains; an N-terminal regulatory domain that binds phos-
phatidylserine, diacylglycerol and, in the case of the classic
isozymes, calcium; and a C-terminal catalytic domain that con-
tains the catalytic center of the enzyme (1, 8).
Individual domains of protein kinase C or mutants that are
truncated or deleted have been used to examine the functions of
different regions of PKC (26, 27), but these mutants have been
of limited value for analysis of PKC isotype function in intact
cells because of their unstable expression, aberrant intracellu-
lar localization, and disregulated enzymatic activity (28–31).
To identify structural determinants of protein kinase C activity
and isozyme-specific functions, we chose a different approach.
We designed PKC chimeras that preserved the overall struc-
ture of native PKC, had inducible kinase activity and could be
found in the soluble cytosolic fraction as well.
PKCg/e chimeras have previously been used in vitro to in-
vestigate the basis of substrate specificity (32). In addition,
PKCa/bII and PKCd/e chimeras were employed to study
isozyme-specific functions in intact cells (33, 34). The catalytic
domain of PKCbII was shown to be responsible for promoting
cell growth in K-562 cells, and the catalytic domain of PKCd is
necessary for PMA-induced differentiation of 32D cells (33, 34).
In the present study, our aim was to define the functional
domains of PKCa, -d, and -e for promoting and inhibiting
growth in NIH 3T3 cells. PKC function is regulated by various
mechanisms. These include activation by diacylglycerol or
phorbol esters, phosphorylation, positional control, and prote-
olysis (2). These mechanisms are tightly connected, and thus it
requires intact isozymes to obtain relevant data on these pro-
cesses. Our chimeras fulfill this requirement, since they can be
stably expressed, display phorbol ester inducible kinase activ-
ity, and show translocation upon PMA treatment. Isotype-spe-
cific effects may arise from each of the above mentioned mech-
anisms. Diacylglycerol or phorbol esters bind to PKC, causing
conformational changes that reveal important sites of interac-
tion on the molecule. These sites include receptor for activated
protein kinase C (RACK)-binding sites that were described in
the regulatory domain (35), but the role of the catalytic domain
in the targeting of PMA-induced translocation has also been
shown2 (20, 33). Other localization signals have been identified
in the regulatory domain of PKCe that appear to determine
2 Wang, Q. J., A´cs, P., Goodnight, J., Blumberg, P. M., Mischak, H.,
and Mushinski, J. F. (1997) Oncogene, in press.
FIG. 4. Effect of PMA and PKC inhibitor GF 109203X on the growth of NIH 3T3 cells that overexpress PKC constructs. NIH 3T3
fibroblasts transfected with PKC chimeras (f) were treated with different concentrations of GF 109203X in the presence of 30 nM PMA. The
number of cells was determined after 7 days of treatment. Points represent the average of three independent experiments 6 S.E. Note that the
same control curve is shown in each panel to show the behavior of the cells that overexpress the empty vector (M).
PKC Chimeras and Cell Growth 28797
whether this isoform associates with the plasma membrane,
the cytoskeleton, or the Golgi apparatus (31). The PKCe/g chi-
mera was likewise shown to display the substrate specificity of
PKCe (32). Phosphorylation occurs on the catalytic domain
rendering the enzymes active and soluble (2).
Our data demonstrate that both the regulatory and the cat-
alytic subunits play roles in cell proliferation. The regulatory
domain of PKCe enhanced cell growth in the absence or pres-
ence of PMA, whereas the role of the catalytic domain of PKCe
was evident in the saturation density of PMA-treated cells that
overexpressed PKCd/e. The important contribution of the PKCe
catalytic domain was also evident in terms of significantly
increased saturation density in the presence of PMA and in
formation of foci upon PMA treatment as well. At the same
time, all chimeras with the PKCe regulatory domain and the
PKCd/e chimera gave rise to colonies in soft agar. Extensive
studies on the tumorigenicity of PKCd and -e chimeras demon-
strate that NIH 3T3 cells that overexpress chimeric PKCd/e,
which contains the PKCe catalytic domain, form tumors in
nude mice.2 These results show that both the regulatory and
catalytic domains of PKC may be responsible for certain
isozyme-specific functions, presumably depending on localiza-
tion or substrate specificity.
Our studies confirmed that overexpressed PKCe is a power-
ful growth stimulus, but we have also shown that chimeras
that substitute the PKCe regulatory domain with that of PKCa
or -d inhibit growth. Cells that overexpress PKCd/e showed cell
growth markedly reduced from cells that overexpress PKCe/e.
PKCd has been generally found to inhibit fibroblast growth (12,
13), but reports on PKCa are equivocal (17, 36–38). In our
studies, overexpressed PKCa inhibited fibroblast growth, and
chimeras that contained either the PKCa, or the PKCd regu-
latory domain inhibited fibroblast growth as well. The translo-
cation pattern and the destination of PKCa/e have been shown
to be chiefly influenced by the catalytic domain of PKCe (20).
Moreover, this isozyme translocates principally into the cy-
toskeletal fraction, appearing in a band showing a higher mo-
bility isoform. This may account for the difference in the effect
on cell growth when compared with PKCd/e. Another possible
mechanism might be a dominant negative effect of PKCa/e on
the endogenous PKCe.
Although tyrosine phosphorylation of PKCd has been dem-
onstrated to occur in response to a variety of stimuli, the
phosphorylation sites and the effect of this phosphorylation on
the activity of the kinase are still unclear (25, 39–41). In vitro
phosphorylation studies revealed three tyrosine phosphoryla-
tion sites in PKCd: two in the regulatory (Tyr-52 and Tyr-155)
and one in the catalytic domain (Tyr-565) (39). We determined
that tyrosine phosphorylation of PKC chimeras upon PDGF
treatment occurred only in chimeras that contained the PKCd
regulatory domain. Assuming that the PKCd is the only ty-
rosine-phosphorylated isozyme, this must be the site of tyro-
sine phosphorylation.
Protein kinases Ca, -d, and -e are nearly ubiquitously ex-
pressed and display opposite effects on cell growth. We con-
structed chimeras to determine the domain responsible for
isozyme-specific effects. The regulatory domains proved to in-
fluence cell growth, but the catalytic domain of PKCe combined
with the PKCd regulatory domain was able to cause a signifi-
cant increase in saturation density and to form colonies in soft
agar. It has been reported that the PKCa regulatory domain
can activate phospholipase D in vitro through a mechanism
that is independent of the kinase activity (42). Studies with
PKCd and -e chimeras on 32D cells also revealed functions that
can be linked to the regulatory domain (34). These data, along
with our data presented here, emphasize that PKC should not
be treated as a simple string of independent domains; rather,
interdomain influences can be important. We can conclude that
both domains are necessary for adequate isozyme-specific func-
tioning of PKC, some of which can be triggered by the regula-
tory, others by the catalytic domain. PKC chimeras thus re-
main important tools to obtain more profound insights into
cellular processes that are brought about by isozyme-specific
PKC activity.
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